W. Kimryn Rathmell, MD, Oncology, Nashville, TN, Vanderbilt University Medical Center

W. KimrynRathmellMDPhD

Oncology Nashville, TN

Genitourinary Oncology, Hematologic Oncology

Chair of Medicine, Physician-in-chief Hugh Jackson Morgan Professor of Medicine Professor of Medicine and Biochemistry, Medical Oncologist

Dr. Rathmell is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rathmell's full profile

Already have an account?

Summary

  • Dr. W. Kimryn Rathmell is an oncologist in Nashville, TN and is affiliated with Vanderbilt University Medical Center, where she currently serves as the Chair of Medicine. She received her medical degree from Stanford University School of Medicine and has been in practice 19 years. She specializes in genitourinary oncology and genetic oncology and is experienced in hematologic oncology, urologic oncology, internal medicine, medical oncology, and hereditary risk associated kidney neoplasms.

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFELLOWSHIP
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemRESIDENCY
  • University of Chicago
    University of ChicagoINTERNSHIP
  • Stanford University School of Medicine
    Stanford University School of MedicineMEDICAL_SCHOOL
  • Stanford UniversityOTHER_TRAINING
  • University of Northern IowaOTHER_TRAINING
  • University of Northern IowaOTHER_TRAINING

Certifications & Licensure

  • AL State Medical License
    AL State Medical License 2020 - 2020
  • TN State Medical License
    TN State Medical License 2015 - 2021
  • NC State Medical License
    NC State Medical License 2003 - 2016
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Alpha Omega Alpha 2013
  • Alpha Omega Alpha (AOA) induction 2014
  • Ruth and Philip Hettelman Award for Scholarly Achievement 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Epigenetic Modifiers: Activities in Renal Cell Carcinoma  
    W. Kimryn Rathmell, MD, Nature
  • A case report of severe type B lactic acidosis following first dose of nivolumab in a VHL-mutated metastatic renal cell carcinoma  
    Nakajima, E, Leger, P, Mauer, IA, Neuss, MN, Chism, DD, Rathmell, WK, Kidney Cancer, 1/1/2017
  • Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas  
    Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis..., Nat Genet, 1/1/2016
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Lectures

  • Renal Cell Carcinoma. 
    Nashville, TN - 1/1/2016
  • Translational Research at the Bioinformatic Edge. 
    Schloss Dagstuhl, Wadern, Germany - 1/1/2016
  • Renal Medullary Carcinoma 
    Nashville, TN - 1/1/2016
  • Join now to see all

Other

  • Tumor Genomics Program 
    Rathmell, WK
    http://university.asco.org/tumor-genomics-program
    ASCO University. - 1/1/2014
  • Comment on autophagy related to VHL gene as a strategy to develop cancer treatments 
    Rathmell, WK, NPR Morning Edition.
    1/1/2008
  • mTOR: An Emerging Pathway in Cancer 
    Rathmell, WK. and Shaw R., Novartis Internal Training Module.
    1/1/2008
  • Join now to see all

Authored Content

  • ASCO Afterthoughts? Many Missions of the Annual MeetingJune 2019
  • ASCO Afterthoughts? Many Missions of the Annual MeetingJune 2019

Grant Support

  • Genetic Events In The Development Of Renal Cell CarcinomaNational Cancer Institute2007–2011
  • Functional And Tissue Specific Effects Of VHL MutationsNational Cancer Institute2003–2007
  • Dendritic Cell Vaccine (Mb-002) To Patients With Metastatic Renal Cell CarcinomaNational Center For Research Resources2006
  • Calgb 90206: Interferon Alfa-2b Or 2B PLUS Bevacizumab In Renal CarcinomaNational Center For Research Resources2006
  • Functional And Tissue Specific Effects Of VHL MutationsNational Cancer Institute2003

Professional Memberships

Hospital Affiliations